Review
Pathology
Nicole C. Panarelli
Summary: Distinguishing inflammatory bowel disease (IBD) from its mimics is challenging for surgical pathologists due to overlapping inflammatory patterns produced by several gastrointestinal infections. Clinical tests may not always be available or reflect ongoing infections. Therefore, surgical pathologists should be knowledgeable about infectious mimics of IBD to generate accurate diagnoses and guide clinical follow-up. This review focuses on bacterial, fungal, and protozoal infections in the differential diagnosis of IBD.
Review
Pharmacology & Pharmacy
Rocio Rivera Rodriguez, Jeremy James Johnson
Summary: Inflammatory Bowel Disease (IBD) is a chronic autoimmune disease characterized by intestinal inflammation. The incidence of IBD is rapidly increasing in newly developed countries, making it a global concern. Two major types of IBD, ulcerative colitis (UC) and Crohn's disease (CD), have different manifestations and locations of inflammation in the digestive tract. Current FDA-approved treatments for IBD are only effective for 50% of patients and come with serious side effects, highlighting the need for safer and more effective therapies. Plant-based diets, such as the Mediterranean diet rich in anti-inflammatory phytochemicals, have shown benefits in preventing and improving symptoms of IBD. Terpenes, a class of phytochemicals abundant in Mediterranean herbs and citrus fruits, have been studied for their potential to modulate inflammatory signaling in IBD. However, there is still conflicting and inconclusive evidence regarding their effectiveness. This review evaluates preclinical studies on terpenes and their impact on basic inflammatory signaling in IBD.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Chemistry, Medicinal
Dandan Liu, Varma Saikam, Katie A. Skrada, Didier Merlin, Suri S. Iyer
Summary: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract, which can be diagnosed through endoscopy and biopsy. However, these methods are expensive and invasive, so alternative noninvasive biomarkers are being explored for disease management and prognosis.
MEDICINAL RESEARCH REVIEWS
(2022)
Review
Gastroenterology & Hepatology
Anna M. Buchner, Yecheskel Schneider, Gary R. Lichtenstein
Summary: Biological therapy targeting tumor necrosis factor-alpha has become crucial in treating patients with inflammatory bowel disease, but high costs limit accessibility. Biosimilars offer the potential to reduce expenditures and increase availability, providing more options for patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Mika Nakayama, Yuki Ozato, Yoshiko Tsuji, Yasuko Arao, Chihiro Otsuka, Yumiko Hamano, Genzo Sumi, Ken Ofusa, Shizuka Uchida, Andrea Vecchione, Hideshi Ishii
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa. Recent studies have shown the involvement of RNA modifications in the specific pathogenesis of IBD. RNA modification-targeting reagents have shown promising outcomes in treating colitis. Understanding RNA modifications in IBD could contribute to early diagnosis, disease monitoring, and innovative therapeutic approaches.
Article
Rheumatology
Clare Harris, J. R. Fraser Cummings
Summary: Primary non-response and secondary loss of response are still significant issues with current treatment options for inflammatory bowel disease, highlighting the need for new therapeutic choices. As our understanding of IBD pathogenesis advances, new therapeutic targets are being identified.
Review
Medicine, General & Internal
Elizabeth A. A. Spencer, Manasi Agrawal, Tine Jess
Summary: This article reviews the available predictors of outcomes in IBD patient and emphasizes the importance of global collaborative efforts and tools to support the clinical use of these prognostication tools.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Bing Chen, Lauren V. Collen, Craig Mowat, Kim L. Isaacs, Siddharth Singh, Sunanda V. Kane, Francis A. Farraye, Scott Snapper, Hani Jneid, Carl J. Lavie, Chayakrit Krittanawong
Summary: This article reviews the association between chronic inflammatory bowel disease and atherosclerotic cardiovascular diseases, heart failure, and atrial fibrillation. The mechanisms underlying this association may involve shared risk factors and pathophysiology. A multidisciplinary team is needed for optimal care.
AMERICAN JOURNAL OF MEDICINE
(2022)
Review
Cell & Tissue Engineering
Yusuke Wakisaka, Shinya Sugimoto, Toshiro Sato
Summary: This review discusses the application of adult tissue-derived organoids culture technology to elucidate the pathogenesis of IBD and to develop novel therapies, including regenerative treatments.
Review
Medicine, General & Internal
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano, Giovanni Maconi
Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Pharmacology & Pharmacy
Linshan Duan, Shuyu Cheng, Long Li, Yanling Liu, Dan Wang, Guoyan Liu
Summary: Inflammatory bowel disease (IBD) is a chronic intestinal inflammation caused by various factors, with Crohn's disease and ulcerative colitis being the two major types. Most commonly used drugs for IBD have adverse reactions and limited long-term efficacy, leading to challenges in treating patients. Research suggests that natural compounds with anti-inflammatory activities could offer potential therapeutic strategies for IBD.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Review
Infectious Diseases
Sara Federici, Denise Kviatcovsky, Rafael Valdes-Mas, Eran Elinav
Summary: Inflammatory bowel disease (IBD) is a group of auto-inflammatory disorders affecting the gastrointestinal tract and other organs. The gut microbiome and specifically bacteriophages, which can infect bacteria, play a role in IBD pathology. Phage therapy shows potential in eradicating pathobionts associated with IBD, but further research is needed.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Review
Pharmacology & Pharmacy
Irene Marafini, Giovanni Monteleone
Summary: Recent advances in understanding the pathogenic mechanisms of inflammatory bowel diseases (IBD) have led to an expansion in therapeutic options, including monoclonal antibodies and small molecule inhibitors. However, treatment efficacy varies and some patients may lose response over time due to the complex and evolving nature of the disease. Personalized approaches to identify the most suitable treatment for individual patients at specific time points may improve drug efficacy and minimize adverse reactions, ultimately benefiting patients' quality of life and reducing costs.
FRONTIERS IN PHARMACOLOGY
(2021)
